159 related articles for article (PubMed ID: 35322299)
1. Histone methyltransferase KMT2C plays an oncogenic role in prostate cancer.
Lian J; Xu C; Chen X; Huang S; Wu D
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1627-1640. PubMed ID: 35322299
[TBL] [Abstract][Full Text] [Related]
2. Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer.
Almeida-Rios D; Graça I; Vieira FQ; Ramalho-Carvalho J; Pereira-Silva E; Martins AT; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Oncotarget; 2016 Aug; 7(33):53018-53028. PubMed ID: 27323813
[TBL] [Abstract][Full Text] [Related]
3. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Lv S; Ji L; Chen B; Liu S; Lei C; Liu X; Qi X; Wang Y; Lai-Han Leung E; Wang H; Zhang L; Yu X; Liu Z; Wei Q; Lu L
Oncogene; 2018 Mar; 37(10):1354-1368. PubMed ID: 29269867
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Chen H; Tu SW; Hsieh JT
J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
[TBL] [Abstract][Full Text] [Related]
5. βKlotho inhibits androgen/androgen receptor‑associated epithelial‑mesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.
Liu Z; Zhang H; Ding S; Qi S; Liu S; Sun D; Dong W; Yin L; Li M; Zhao X; Lu J
Oncol Rep; 2018 Jul; 40(1):217-225. PubMed ID: 29749458
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-132/212 Upregulation Inhibits TGF-β-Mediated Epithelial-Mesenchymal Transition of Prostate Cancer Cells by Targeting SOX4.
Fu W; Tao T; Qi M; Wang L; Hu J; Li X; Xing N; Du R; Han B
Prostate; 2016 Dec; 76(16):1560-1570. PubMed ID: 27527117
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of CUL4A in human prostate cancer.
Liu G; Zhu Z; Lang F; Li B; Gao D
Tumour Biol; 2015 Nov; 36(11):8553-8. PubMed ID: 26036759
[TBL] [Abstract][Full Text] [Related]
8. KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis.
Limberger T; Schlederer M; Trachtová K; Garces de Los Fayos Alonso I; Yang J; Högler S; Sternberg C; Bystry V; Oppelt J; Tichý B; Schmeidl M; Kodajova P; Jäger A; Neubauer HA; Oberhuber M; Schmalzbauer BS; Pospisilova S; Dolznig H; Wadsak W; Culig Z; Turner SD; Egger G; Lagger S; Kenner L
Mol Cancer; 2022 Mar; 21(1):89. PubMed ID: 35354467
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.
Almeida M; Costa VL; Costa NR; Ramalho-Carvalho J; Baptista T; Ribeiro FR; Paulo P; Teixeira MR; Oliveira J; Lothe RA; Lind GE; Henrique R; Jerónimo C
J Cell Mol Med; 2014 Nov; 18(11):2287-97. PubMed ID: 25211630
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.
Ren D; Yang Q; Dai Y; Guo W; Du H; Song L; Peng X
Mol Cancer; 2017 Jul; 16(1):117. PubMed ID: 28693582
[TBL] [Abstract][Full Text] [Related]
12. Epigenetics-related genes in prostate cancer: expression profile in prostate cancer tissues, androgen-sensitive and -insensitive cell lines.
Adler D; Lindstrot A; Ochsenfahrt J; Fuchs K; Wernert N
Int J Mol Med; 2013 Jan; 31(1):21-5. PubMed ID: 23135352
[TBL] [Abstract][Full Text] [Related]
13. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
Vieira FQ; Costa-Pinheiro P; Almeida-Rios D; Graça I; Monteiro-Reis S; Simões-Sousa S; Carneiro I; Sousa EJ; Godinho MI; Baltazar F; Henrique R; Jerónimo C
Oncotarget; 2015 May; 6(15):13644-57. PubMed ID: 25980436
[TBL] [Abstract][Full Text] [Related]
14. SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms.
García-Tobilla P; Solórzano SR; Salido-Guadarrama I; González-Covarrubias V; Morales-Montor G; Díaz-Otañez CE; Rodríguez-Dorantes M
Gene; 2016 Nov; 593(2):292-301. PubMed ID: 27570179
[TBL] [Abstract][Full Text] [Related]
15. TUG1 promotes the development of prostate cancer by regulating RLIM.
Guo BH; Zhao Q; Li HY
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1926-1933. PubMed ID: 30915735
[TBL] [Abstract][Full Text] [Related]
16. Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.
White-Al Habeeb NM; Garcia J; Fleshner N; Bapat B
Prostate; 2016 Dec; 76(16):1507-1518. PubMed ID: 27404348
[TBL] [Abstract][Full Text] [Related]
17. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.
Ezponda T; Popovic R; Shah MY; Martinez-Garcia E; Zheng Y; Min DJ; Will C; Neri A; Kelleher NL; Yu J; Licht JD
Oncogene; 2013 Jun; 32(23):2882-90. PubMed ID: 22797064
[TBL] [Abstract][Full Text] [Related]
18. Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4.
Schagdarsurengin U; Lammert A; Schunk N; Sheridan D; Gattenloehner S; Steger K; Wagenlehner F; Dansranjavin T
Cell Commun Signal; 2017 Oct; 15(1):40. PubMed ID: 29017567
[TBL] [Abstract][Full Text] [Related]
19. Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4.
Zhang J; Shen C; Wang L; Ma Q; Xia P; Qi M; Yang M; Han B
Biochem Biophys Res Commun; 2014 Sep; 452(3):746-52. PubMed ID: 25201727
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer.
Sinha KM; Bagheri-Yarmand R; Lahiri S; Lu Y; Zhang M; Amra S; Rizvi Y; Wan X; Navone N; Ozpolat B; Logothetis C; Gagel RF; Huard J
Oncogene; 2019 Jun; 38(25):5038-5049. PubMed ID: 30858546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]